Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Operating Leases (2019 - 2025)

Historic Operating Leases for Assembly Biosciences (ASMB) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • Assembly Biosciences' Operating Leases rose 185309.73% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 185309.73%. This contributed to the annual value of $2.6 million for FY2024, which is 13422.46% up from last year.
  • Assembly Biosciences' Operating Leases amounted to $2.2 million in Q3 2025, which was up 185309.73% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Operating Leases peaked at $5.6 million during Q1 2021, and registered a low of $50000.0 during Q3 2023.
  • In the last 5 years, Assembly Biosciences' Operating Leases had a median value of $1.8 million in 2022 and averaged $1.9 million.
  • Per our database at Business Quant, Assembly Biosciences' Operating Leases plummeted by 9696.24% in 2022 and then surged by 185309.73% in 2025.
  • Over the past 5 years, Assembly Biosciences' Operating Leases (Quarter) stood at $3.3 million in 2021, then plummeted by 96.96% to $101000.0 in 2022, then soared by 1010.89% to $1.1 million in 2023, then skyrocketed by 134.22% to $2.6 million in 2024, then dropped by 16.02% to $2.2 million in 2025.
  • Its Operating Leases was $2.2 million in Q3 2025, compared to $2.4 million in Q2 2025 and $2.5 million in Q1 2025.